Lung cancer organoids analyzed on microwell arrays predict drug responses of patients within a week
Yawei Hu(Tsinghua University), Peng Liu(People's Hospital of Cangzhou), Kaiyi Li(Yunnan Normal University), Fan Yang(First People's Hospital of Yunnan Province), Binbin Zou, Zhongyao Chen(Tsinghua University), Xiuyuan Chen(Peking University), Yaohua Zhang(Beihang University), Jun Wang(Peking University), Qiang Liu(China Agricultural University), Xiaofang Chen(Peking University), Yaqian Li(Beihang University), Cong Li, Xianning Wang, Xizhao Sui(Peking University), Fan Song(Beihang University)
Cited by 261
Related Papers
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
|Annals of Oncology|2021|724
LncRNA DILA1 inhibits Cyclin D1 degradation and contributes to tamoxifen resistance in breast cancer
|Nature Communications|2020|194